AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04749459
Drug: ISO 24444:2010 P2 Standard Reference Sunscreen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single topical application of ISO 24444:2010 P2 Standard Sunscreen will be applied to the appropriate 40 cm\^2 test site (on the back of each participants). This application shall provide a test material film of approximately 2.00 +/- 0.05 mg/cm\^2, using 80 +/-2 mg of material.
Trial: NCT05630209
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin infusion
Trial: NCT05521230
Drug: Placebo Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of mouthwashes
Trial: NCT05521230
Drug: Cymenol mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of mouthwashes
Trial: NCT05209633
Drug: Granules Dendrobii
RxNorm normalized name: Dendrobium moniliforme whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6g each, 3 times per day, total 18 weeks
Trial: NCT05209633
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT04839731
Drug: Combination topical 5-fluorouracil 5% / calcipotriene 0.005% cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply twice per day for allotted time
Trial: NCT04839731
Drug: Nourivan Base Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply twice per day for allotted time
Trial: NCT05245760
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (AUC2) and Paclitaxel (50mg/m2), Weekly x 5 weeks
Trial: NCT06560528
Drug: combination with Disitamab Vedotin and with Tislelizumab and Capecitabine
RxNorm normalized name: Disitamab vedotin
DrugBank: Disitamab vedotin (DB17208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive Disitamab Vedotin combined with Tislelizumab and Capecitabine for 3 cycles (Q3W) in the neoadjuvant phase and 5 cycles (Q3W) of treatment in the adjuvant phase.~1. Disitamab Vedotin：2.5 mg/kg，Q3W；~2. Tislelizumab：200 mg，Q3W；~3. Capecitabine：1000 mg /m2, PO, bid d1-14, Q3W.
Trial: NCT02317263
Drug: testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02317263
Drug: placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05677555
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 25 subjects will be randomized to treatment with matched placebo, three times a week (at the end of each hemodialysis session) over the 3 month study period.
Trial: NCT05016323
Drug: HR19042 Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR19042 Capsules
Trial: NCT05016323
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05374538
Drug: VIC-1911
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIC-1911 tablets for oral administration
Trial: NCT04870606
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo+Standard of care determined by PI and local regulatory
Trial: NCT02054260
Drug: Surgicel
RxNorm normalized name: Surgicel SNoW 4x4"
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05965284
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients included into this study will be treated with Azathioprine tablets 100mg QD for 12 months.
Trial: NCT06428669
Drug: Nitro-Bid 2 % Topical Ointment
RxNorm normalized name: Nitro-Bid 2 % Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group will get 30mg of Nitro-Bid topical ointment applied over the chest (15mg/ 1 packet on each side) one time intra-operatively
Trial: NCT05098990
Drug: Jinfukang oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jinfukang koufuye is a Chinese herbal prescription, which is used in treatment for patients with NSCLC in clinical practice. It has been proved to be capable of preventing the occurrence of metastasis, stabilizing tumor lesions, improving the response rates when combined with chemotherapy, and prolonging the survival period of lung cancer patients.
Trial: NCT05667129
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule formulation
Trial: NCT05091320
Drug: medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medical management of patient according guide lines, either alteplase if presented in it's time window, or anti-platelet
Trial: NCT04756713
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conventional chemotherapy will be treated with MTX (1 mg/kg intramuscular) with rescue of FA (15mg orally). In cases of chemoresistance, second-line chemotherapy will be performed with actinomycin-D (Act-D) 1.25 mg intravenous pulse every 14 days. The third line of chemotherapy will be the EMA/CO regimen (, reserving the EP / EMA regimen (E, cisplatin, MTX / Act-D) for the fourth line.
Trial: NCT05429567
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients underwent combined spinal and epidural anesthesia (CSEA) with 2 ml of 0.5 % hyperbaric bupivacaine and 25 ug fentanyl administered using a 27-gauge Whitacre spinal needle and an 18-gauge Tuohy needle in the epidural space. The epidural space was identified utilizing the loss of resistance approach
Trial: NCT04738539
Drug: Contrast Enhanced Voiding Urosonography with Urodynamic Testing
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We will be using contrast enhanced voiding urosonography to image urodynamic testing on patients with neurogenic bladder.
Trial: NCT06093932
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 capsules at a time, three times a day, duration: 12 weeks
Trial: NCT05641324
Drug: ANV419
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANV419 administered by intravenous (IV) infusion
Trial: NCT05957991
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with placebo
Trial: NCT04906980
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo (PEG400) will be administered orally.
Trial: NCT06400355
Drug: Ringer's Lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: similar volume of the infused mannitol but of lactated Ringer will be given 30 minutes before the end of the surgery.
Trial: NCT05108779
Drug: QLF32004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the phase, five dose groups were proposed.The frequency of administration was once a week, and the treatment cycle was 3 weeks.
Trial: NCT05170594
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The non-platinum chemotherapy regimen will be determined by the investigator.
Trial: NCT04879043
Drug: HDP-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDP-101 is available as lyophilized white powder for preparation of infusion.
Trial: NCT05622526
Drug: Group 1 or Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules of fecal microbiota transplantation
Trial: NCT06206174
Drug: TGRX-814
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants are given TGRX-814 tablets for oral, once daily administration at one of the dose levels as pre-determined for the dose escalation sequence.
Trial: NCT05294055
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 50mg/kg or 2g/m2, for 2 days
Trial: NCT05716880
Drug: Ketosteril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose = 1 tabl / 5 kg of ideal body weight
Trial: NCT06515405
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cohort members will be considered to be exposed to early hydrocortisone if either:~1. They receive early hydrocortisone started on postnatal day 1 or 2 and given for more than seven consecutive days OR~2. They receive early hydrocortisone started on postnatal day 1 or 2 and are being cared for in a PROHYDRO unit but die on or before postnatal day 8.~PROHYDRO units are defined as units who, at the time the baby was born, had implemented a protocol for use of prophylactic hydrocortisone as part of routine care for babies born less than 28 weeks' gestation. A unit may change from being a non-PROHYDRO unit to a PROHYDRO unit if a new early hydrocortisone protocol is introduced during the study period (2016-2023).
Trial: NCT04704232
Drug: ACD440
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double blind, parallel within subject comparison
Trial: NCT04766021
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control condition
Trial: NCT05172947
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group received placebo with the conventional therapy
Trial: NCT05169710
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet (supplied in two tablets)
Trial: NCT05841043
Drug: SHR8028 eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR8028 eye drops
Trial: NCT05841043
Drug: Vehicle eye drops.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle eye drops.
Trial: NCT06443151
Drug: Acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endothelium-dependent vasodilation will then be assessed by changes in FBF in response to intra-arterial infusions of the endothelial agonist acetylcholine infused at rates of 4.0, 8.0, 16.0 μg/100 mL of forearm tissue/min to generate a dose-response curve.
Trial: NCT06443151
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid will be infused at a constant rate (12 mg/100 mL tissue/min) and maintained at the same rate while the acetylcholine and sodium nitroprusside dose-response curves are repeated.
Trial: NCT06233071
Drug: Drospirenone+ Ethinyl Estradiol Tablets-Test product
RxNorm normalized name: drospirenone / ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Manufactured by: POND'S CHEMICAL THAILAND R.O.P
Trial: NCT06233071
Drug: Drospirenone+ Ethinyl Estradiol Tablets-Reference product
RxNorm normalized name: drospirenone / ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Manufactured by: Bayer Weimar GmbH und Co. KG, Germany
Trial: NCT01868048
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oromucosal spray, containing no active drug but ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorants. Maximum permitted dose is 10 actuations per day.
Trial: NCT04739046
Drug: Theragene arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theragene®,Ad5-yCD/ mutTKSR39rep-ADP with radiation therapy
Trial: NCT06558708
Drug: GZR101 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily
Trial: NCT06558708
Drug: GZR33 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily
Trial: NCT05797701
Drug: SAR443820
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet by oral administration
Trial: NCT05893576
Drug: HRS9531
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive a single dose of HRS9531 of original formulation.
Trial: NCT06168214
Drug: Rabeprazloe+bismuth+amoxicillin+clarithromycin
RxNorm normalized name: lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PBAC: 14D: PPI: Rabeprazole 10mg bid; B: bismuth potassium citrate240mg bid/ colloidal bismuth pectin 300mg bid/ colloidal bismuth tartrate 220mg bid; A:amoxicillin1000mg bid; C: clarithromycin 500mg bid.
Trial: NCT06168214
Drug: Vonoprazan+amoxicillin+clarithromycin 14 days
RxNorm normalized name: clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VAC14: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg bid; C: clarithromycin 500mg bid.
Trial: NCT05797701
Drug: SAR443820
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule by oral administration
Trial: NCT04631562
Drug: ALXN1820 SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALXN1820 SC will be administered as a manual SC push or SC infusion via a syringe pump. Doses will range from 12.5 milligrams (mg) to a maximum of 2250 mg. Multiple dosing duration will range from 3 to 5 weeks.
Trial: NCT04631562
Drug: ALXN1820 IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALXN1820 IV (450 mg) will be administered as an IV infusion.
Trial: NCT04631562
Drug: Placebo SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo SC will be administered as a manual SC push or SC infusion via a syringe pump.
Trial: NCT04631562
Drug: Placebo IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV will be administered as an IV infusion.
Trial: NCT06380816
Drug: UCB4594
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive UCB4594 as an intravenous infusion once every 3 weeks for up to 18 cycles, with each cycle lasting 21 days (\~1 year).
Trial: NCT05893576
Drug: HRS9531
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive a single dose of HRS9531 of new formulation.
Trial: NCT06168214
Drug: Vonoprazan+amoxicillin+clarithromycin 7 days
RxNorm normalized name: AMOXICILLIN/CLARITHROMYCIN/VONOPRAZAN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAC7: 7D: V: vonoprazan 20mg bid; A: amoxicillin1000mg bid; C: clarithromycin 500mg bid.
Trial: NCT06168214
Drug: Vonoprazan+tetracycline+furazolidone 14 days
RxNorm normalized name: Furazolidone
DrugBank: Furazolidone (DB00614)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VTF14: 14D: V: vonoprazan 20mg bid; T: tetracycline 500mg tid; F: furazolidone 100mg bid.
Trial: NCT05042310
Drug: LY3541860
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered either IV or SC.
Trial: NCT05042310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered either IV or SC.
Trial: NCT06168214
Drug: Vonoprazan+tetracycline+furazolidone 7 days
RxNorm normalized name: Furazolidone
DrugBank: Furazolidone (DB00614)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VTF7: 7D: V: vonoprazan 20mg bid; T: tetracycline 500mg tid; F: furazolidone 100mg bid.
Trial: NCT06168214
Drug: Vonoprazan+amoxicillin+tetracycline 14 days
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: hVAT: 14D: V: vonoprazan 20mg bid; A: amoxicillin1000mg tid; T: tetracycline 500mg tid.
Trial: NCT06216639
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg film-coated tablets. Prescribed only for the primary treatment with bismuth-based quadruple therapy in participants with active H. pylori infection who are allergic to penicillin. The prescribed daily dose is 500 mg BID for a period of 14 days.
Trial: NCT06103201
Drug: Hyperpolarized 13C-Pyruvate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperpolarized Pyruvate (13C) Injection, containing spin-polarized (hyperpolarized) \[13C\]pyruvate, is being studied as a diagnostic agent in combination with 13C spectroscopic MR imaging. The aim is to visualize \[13C\]pyruvate and its metabolites and thereby distinguish between anatomical areas with normal vs. abnormal metabolism, which should be useful in diagnosing and characterizing, for example, traumatic brain injury.~Hyperpolarized Pyruvate (13C) Injection and \[13C\]pyruvate are general terms used throughout this brochure, which refer to all 13C labeling patterns, such as \[1- 13C\]pyruvate, \[2- 13C\]pyruvate and \[1,2- 13C\]pyruvate. From biological and safety standpoints, pyruvate with each of the labeling patterns behaves identically in the human body \[Koletzko et al., 1997\].
Trial: NCT06009874
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will be treated with a placebo tab once daily for three months
Trial: NCT06383273
Drug: Placebo sublingual tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each dose of placebo will be provided as a matching sublingual tablet, containing placebo. Participants will receive 1 sublingual tablet of study medication 30 (± 5) minutes prior to planned surgery start, without food or water.
Trial: NCT03593252
Drug: Sodium Picosulfate, Magnesium Oxide and Citric Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laxative used for bowel preparation
Trial: NCT00002309
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05527457
Drug: BAY2586116
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 μg BAY2586116 nasal spray application
Trial: NCT05527457
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline) nasal spray application
Trial: NCT05707325
Drug: engineered red blood cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: engineered red blood cell
Trial: NCT06484790
Drug: NW-301V
RxNorm normalized name: DRESSING,HYDRASORB 4IN X 4IN KEN#1694-NW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCR-T T cell targeting KRAS G12V mutation
Trial: NCT06484790
Drug: NW-301D
RxNorm normalized name: DRESSING,HYDRASORB 4IN X 4IN KEN#1694-NW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCR-T T cell targeting KRAS G12D mutation
Trial: NCT05571787
Drug: HMPL-523
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 700 mg HMPL-523 will be administered by mouth once daily on Day 1, Day 8, Day 15, and Day 26
Trial: NCT01523379
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl i.v. two times a day, two days in an row
Trial: NCT05013463
Drug: Indapamide Pill
RxNorm normalized name: indapamide Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Indapamide, 2.5 mg OD
Trial: NCT03824847
Drug: Clarithromycin 250 MG
RxNorm normalized name: clarithromycin 250 MG
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin 1 tablet (250mg) twice daily for three days
Trial: NCT03824847
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group: (identical-looking) placebo 1 tablet twice daily for three days
Trial: NCT04813471
Drug: Endothelial Protocol
RxNorm normalized name: endothelial growth factor A, vascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endothelial Protocol
Trial: NCT06377826
Drug: medication
RxNorm normalized name: Acne Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group will be just on medication and no exercise will be given to this group
Trial: NCT05361330
Drug: Shuganjieyu capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules each time, twice per day. According to the study progress, the intervention can be adjusted to 4 capsules each time, twice per day
Trial: NCT05361330
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication in basic study period: Fluoxetine (20 mg, once a day) Medication in the expanded study period: After 8 weeks of basic study period, if the reduction rate of HAMD-17 total scores is below 50 %, for the treatment group, the dosage of Fluoxetine will be adjusted to 40 mg / time, once a day.
Trial: NCT04746963
Drug: AXT107 0.1 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravitreal injection of AXT107 0.1 mg/eye (low dose)
Trial: NCT04746963
Drug: AXT107 0.25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravitreal injection of AXT107 0.25 mg/eye (mid dose)
Trial: NCT04746963
Drug: AXT107 0.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravitreal injection of AXT107 0.5 mg/eye (high dose)
Trial: NCT06509568
Drug: Neoadjuvant chemoimmunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the nCIT group will receive two cycles of TC chemotherapy combined with immunotherapy, specifically paclitaxel (albumin-bound) 100 mg/m² on days 1, 8, 15 or 260mg/m² d1, carboplatin (AUC=5) on days 1, and toripalimab (200 mg) on days 1. Minimally invasive esophagectomy will be performed 4-6 weeks after completing chemotherapy, and adjuvant immunotherapy is recommended for one year after surgery.
Trial: NCT04938635
Drug: VIT-2763 60 mg QD
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants receive one VIT-2763 60 mg capsule plus one Placebo capsule orally in the morning, and 2 Placebo capsules orally in the evening, for 24 weeks.
Trial: NCT04938635
Drug: VIT-2763 60 mg BID
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants receive one VIT-2763 60 mg capsule plus one Placebo capsule orally, twice daily for 24 weeks.
Trial: NCT04938635
Drug: VIT-2763 120 mg BID
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants receive two VIT-2763 60 mg capsules orally, twice daily for 24 weeks.
Trial: NCT04938635
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive two Placebo capsules matching VIT-2763 orally, twice daily for 24 weeks.
Trial: NCT00000640
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06324825
Drug: Fuzhegn Nizeng Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects taking prepared Fuzhegn Nizeng granules twice daily for 6 month.